1. Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective 
Bruno Salgado Riveros, MSc, Patrícia Klarmann Ziegelmann, PhD, Cassyano Januário Correr, PhD 
Value in Health Regional Issues 
Volume 5, Pages (December 2014)
DOI: /j.vhri
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Markov model for patients with moderate-to-severe psoriasis treated with biologics. PASI, Psoriasis Area Severity Index.
Value in Health Regional Issues 2014 5, 65-72DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Tornado diagram expressed in terms of ICER impact. (A) Etanercept (ETA) vs. adalimumab (ADA). (B) Infliximab (INF) vs. adalimumab. (C) Ustekinumab (UST) vs. adalimumab. ICER, incremental cost-effectiveness ratio.
Value in Health Regional Issues 2014 5, 65-72DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Time-horizon analysis from 1 to 5 years and its impact on the cost-effectiveness ratio. The horizontal line represents the time horizon expressed in years.
Value in Health Regional Issues 2014 5, 65-72DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5. Fig. 4
Cost-effectiveness acceptability curve. Willingness to pay for each incremental case of PASI75 varies between R$50,000 and R$500,000.
Value in Health Regional Issues 2014 5, 65-72DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions